EA201990868A1 - СОЕДИНЕНИЯ И СПОСОБЫ АКТИВАЦИИ СИГНАЛЬНОЙ СИСТЕМЫ Tie2 - Google Patents

СОЕДИНЕНИЯ И СПОСОБЫ АКТИВАЦИИ СИГНАЛЬНОЙ СИСТЕМЫ Tie2

Info

Publication number
EA201990868A1
EA201990868A1 EA201990868A EA201990868A EA201990868A1 EA 201990868 A1 EA201990868 A1 EA 201990868A1 EA 201990868 A EA201990868 A EA 201990868A EA 201990868 A EA201990868 A EA 201990868A EA 201990868 A1 EA201990868 A1 EA 201990868A1
Authority
EA
Eurasian Patent Office
Prior art keywords
tie2
methods
activating
connections
signal system
Prior art date
Application number
EA201990868A
Other languages
English (en)
Inventor
Ниранджан Б. Пандей
Адам Мирандо
Александер С. Попел
Джордан Дж. Грин
Original Assignee
Асклепикс Терапьютикс, Инк.
Дзе Джонс Хопкинс Юниверсити
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Асклепикс Терапьютикс, Инк., Дзе Джонс Хопкинс Юниверсити filed Critical Асклепикс Терапьютикс, Инк.
Publication of EA201990868A1 publication Critical patent/EA201990868A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • A61K47/6937—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol the polymer being PLGA, PLA or polyglycolic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Настоящее изобретение в разнообразных аспектах и вариантах осуществления включает способы лечения проницаемости сосудов, связанной с Tie2, путем введения одного или более биомиметических пептидов, полученных из коллагена IV, и включает композиции для лечения проницаемости сосудов, связанной с Tie2, содержащие один или более биомиметических пептидов, полученных из коллагена IV. Такие пептиды могут усиливать агонистическую активность ангиопоэтина 2 (Ang2) в отношении Tie2, тем самым стабилизируя сосудистую систему и/или лимфатические сосуды.
EA201990868A 2016-10-04 2017-10-04 СОЕДИНЕНИЯ И СПОСОБЫ АКТИВАЦИИ СИГНАЛЬНОЙ СИСТЕМЫ Tie2 EA201990868A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662403786P 2016-10-04 2016-10-04
PCT/US2017/055055 WO2018067646A1 (en) 2016-10-04 2017-10-04 Compounds and methods for activating tie2 signaling

Publications (1)

Publication Number Publication Date
EA201990868A1 true EA201990868A1 (ru) 2019-09-30

Family

ID=61832135

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201990868A EA201990868A1 (ru) 2016-10-04 2017-10-04 СОЕДИНЕНИЯ И СПОСОБЫ АКТИВАЦИИ СИГНАЛЬНОЙ СИСТЕМЫ Tie2

Country Status (14)

Country Link
US (1) US20190225670A1 (ru)
EP (1) EP3522906B1 (ru)
JP (1) JP2019535651A (ru)
KR (1) KR20190066040A (ru)
CN (1) CN110177563A (ru)
AU (1) AU2017339970A1 (ru)
BR (1) BR112019006735A2 (ru)
CA (1) CA3038809A1 (ru)
EA (1) EA201990868A1 (ru)
IL (1) IL265694A (ru)
MX (1) MX2019003895A (ru)
SG (1) SG10202103032QA (ru)
WO (1) WO2018067646A1 (ru)
ZA (1) ZA201902344B (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2473565C2 (ru) 2006-04-07 2013-01-27 Аерпио Терапетикс, Инк. АНТИТЕЛА, СВЯЗЫВАЮЩИЕ ТИРОЗИН ФОСФАТАЗУ БЕТА ЧЕЛОВЕКА (HPTPβ), И ИХ ИСПОЛЬЗОВАНИЕ
KR20200003859A (ko) * 2017-05-08 2020-01-10 아스클리픽스 테라퓨틱스, 인크. 항-혈관신생 펩티드의 지속적인 운반을 위한 생물분해가능한 미립자
US11674959B2 (en) 2017-08-03 2023-06-13 The Johns Hopkins University Methods for identifying and preparing pharmaceutical agents for activating Tie1 and/or Tie2 receptors
WO2020068653A1 (en) 2018-09-24 2020-04-02 Aerpio Pharmaceuticals, Inc. MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - β (VE-PTP) AND VEGF
EP3946418A4 (en) * 2019-03-26 2023-02-22 Asclepix Therapeutics, Inc. COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASE
CN117126233A (zh) * 2022-05-20 2023-11-28 杭州禾泰健宇生物科技有限公司 一种类肽化合物及其应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5475096A (en) 1990-06-11 1995-12-12 University Research Corporation Nucleic acid ligands
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US6004746A (en) 1994-07-20 1999-12-21 The General Hospital Corporation Interaction trap systems for detecting protein interactions
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
DE60026695T2 (de) 1999-05-05 2006-11-02 Phylogica Ltd., Northbridge ISOLIERUNG VON BIOLOGISCHEN MODULATOREN AUS BIBIOTHEKEN MIT BIOLOGISCH VIELFäLTIGEN GENFRAGMENTEN
CA2374180C (en) 1999-05-26 2012-09-11 Marita Hiipakka Methods and materials for generating sh3 domains with tailored binding properties
SE0001877D0 (sv) 2000-05-22 2000-05-22 Klaus Mosbach Molecular imprinting
CA2421447C (en) 2000-09-08 2012-05-08 Universitat Zurich Collections of repeat proteins comprising repeat modules
DE10053224A1 (de) 2000-10-26 2002-05-08 Univ Goettingen Georg August Verfahren zur Exposition von Peptiden und Polypeptiden auf der Zelloberfläche von Bakterien
US20040132094A1 (en) 2000-12-13 2004-07-08 Michael Etzerodt Combinatorial libraries of proteins having the scaffold structure of c-type lectinlike domains
AU2002323501C1 (en) 2001-08-30 2010-04-29 Biorexis Technology, Inc Modified transferrin fusion proteins
KR20120088836A (ko) 2002-10-02 2012-08-08 리전츠 오브 더 유니버시티 오브 캘리포니아 변경된 특이성을 갖는 프로테아제의 제조 및 선별 방법
EP1587907B1 (en) 2003-01-07 2011-03-02 Dyax Corporation Kunitz domain library
US20060008844A1 (en) 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
DE102004049479A1 (de) 2004-10-11 2006-04-13 Scil Proteins Gmbh Proteinkonjugate zur Verwendung in Therapie, Diagnose und Chromatographie
US20100144641A1 (en) * 2005-09-12 2010-06-10 Popel Aleksander S Compositions Having Antiangiogenic Activity and Uses Thereof
EP1892248A1 (en) 2006-08-21 2008-02-27 Eidgenössische Technische Hochschule Zürich Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase
MX2009013004A (es) 2007-06-01 2010-01-20 Univ Maryland Agentes de union al receptor de la region constante fc de inmunoglobulina.
ES2554812T3 (es) * 2007-11-09 2015-12-23 Genentech, Inc. Composiciones de antagonistas de quinasa 1 de tipo receptor de activina y métodos de uso
US9051349B2 (en) 2007-11-21 2015-06-09 Alba Therapeutics Corporation Larazotide acetate compositions
MX2012000383A (es) * 2009-07-07 2012-06-01 Normoxys Inc Método para reducir la resistencia a terapias multidroga utilizando tripirofosfato de inositol.
EP2649095B1 (en) 2010-12-10 2021-10-06 Aleksander S. Popel Mimetic peptides derived from collagen type iv and their use for treating angiogenesis- and lymphangiogenesis- dependent diseases
JP2015500296A (ja) 2011-12-09 2015-01-05 ザ・ジョンズ・ホプキンス・ユニバーシティ 定義された動的形状を有する人工抗原提示細胞
EP3643318A1 (en) * 2013-06-07 2020-04-29 The Johns Hopkins University A biomimetic peptide and biodegradable delivery platform for the treatment of angiogenesis- and lymphangiogenesis-dependent diseases

Also Published As

Publication number Publication date
EP3522906A1 (en) 2019-08-14
AU2017339970A1 (en) 2019-04-18
SG10202103032QA (en) 2021-05-28
KR20190066040A (ko) 2019-06-12
JP2019535651A (ja) 2019-12-12
US20190225670A1 (en) 2019-07-25
CA3038809A1 (en) 2018-04-12
BR112019006735A2 (pt) 2019-06-25
EP3522906A4 (en) 2020-06-10
MX2019003895A (es) 2019-10-07
WO2018067646A1 (en) 2018-04-12
CN110177563A (zh) 2019-08-27
ZA201902344B (en) 2021-09-29
EP3522906B1 (en) 2022-03-23
IL265694A (en) 2019-05-30

Similar Documents

Publication Publication Date Title
EA201990868A1 (ru) СОЕДИНЕНИЯ И СПОСОБЫ АКТИВАЦИИ СИГНАЛЬНОЙ СИСТЕМЫ Tie2
EA201890640A1 (ru) Рекомбинантные векторы, содержащие пептид 2а
EA201791775A1 (ru) Цистеиновая протеаза
MX2021006017A (es) Polipeptidos de folistatina y sus usos.
GEP20217326B (en) Constructs having a sirp-alpha domain or variant thereof
ZA201705113B (en) Cysteine protease
PH12017502103A1 (en) Methods and kits for treating depression
EA201792182A1 (ru) Композиции и способы для лечения анемии
EA201691978A1 (ru) Соединения в качестве модуляторов ror гамма
CY1124761T1 (el) Ρυθμιστες της δραστικοτητας του συμπληρωματος
MX2021008318A (es) Nuevos polipeptidos de union especifica y usos de los mismos.
EA201791467A1 (ru) Водный офтальмологический раствор
EA201990298A1 (ru) Способы и композиции для лечения рака
EA202090457A1 (ru) Комбинированная терапия ласмидитаном и антагонистом cgrp для применения в лечении мигрени
EA201792262A1 (ru) Пироглутамат вортиоксетина
EA201892631A1 (ru) Дигидротестостерон и производные и промоторы дигидротестостерона в лечении рака
MX2020005555A (es) Construcciones inmunogenicas de peptidos de tau.
MX2015002279A (es) Peptido pntx(19) sintético, composición farmacéutica.y uso.
EA202090427A1 (ru) Композиции и способы лечения атопического дерматита и выбора лечения
EA201790623A1 (ru) Аденовирусный вектор, кодирующий гомологог-1 белка atonal человека (hath1)
NZ751995A (en) Modified factor h binding protein
NZ738982A (en) Composition comprising amino acid and cyclic dipeptide
MY186302A (en) Beta-caseins and gut microbiota
NZ734845A (en) Use of short synthetic peptide for the treatment and/or prophylaxis of dry eye disease
EA201890209A1 (ru) Композиция, содержащая танины